

**MARKSANS PHARMA LIMITED**

Regd. Office: 601-622, Chintamani Plaza, Mohan Studio Compd, A.K.Road, Andheri [East], Mumbai-400099  
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2006

(Rs. In lacs)

Sr. No.	PARTICULARS	Quarter ended		nine months ended		Year ended
		31st Dec. 06 (UNAUDITED)	31st Dec. 05 (UNAUDITED)	31st Dec. 06 (UNAUDITED)	31st Dec. 05 (UNAUDITED)	31st March 06 (AUDITED)
1	Net sales /Income from Operations	7,225.46	7,209.18	21,410.00	24,683.35	29,185.45
2	Other Income	235.29	132.46	880.16	212.29	471.17
3	Total Expenditure	6,223.04	6,276.31	18,556.20	20,497.10	24,685.36
	-(Increase) /Decrease in Stock in trade	(247.66)	(1,389.28)	(892.51)	(814.33)	(2,355.44)
	-Consumption of Raw Material	5,269.48	6,601.62	15,844.21	18,030.16	22,648.37
	-Staff Cost	289.46	233.06	806.79	586.46	947.11
	-Other Expenditure	911.76	830.91	2,797.71	2,694.81	3,445.32
4	Interest	288.91	214.17	816.50	801.79	1,035.08
5	Depreciation	216.46	143.80	753.09	697.34	803.98
6	Profit/(Loss) before Ta	732.34	707.36	2,164.37	2,899.41	3,132.20
7	Provision for Taxation	127.09	105.13	397.09	257.04	814.24
8	Net Profit /(Loss)	605.25	602.23	1,767.28	2,642.37	2,317.96
9	Add/Less :Short provision/ Prior period expenses		-		-	29.53
10	Net Profit/( after extra ordinary items	605.25	602.23	1,767.28	2,642.37	2,288.43
11	Paid up Equity Share Capital (Face value Rs. 10 per share)	3,594.06	3,594.06	3,594.06	3,594.06	3,594.06
12	Reserves and Surplus ( Excluding Revaluation Reserve)				-	5,286.46
13	Basic and Diluted EPS for the period (Not annualised)	1.68	1.68	4.92	7.35	6.37
14	Non -Promoter share holding					
	-Number of Shares	18776527	18575527	18776527	18575527	18778569
	-Percentage of Share holding	52.24%	51.68%	52.24%	51.68%	52.25%

Notes:

- The above results were taken on records at the Board meeting held on 31-01-2007
- The details of investor complaints during the quarter is as under:  
Opening Balance : NIL, Received & Resolved during the quarter : 4, Pending as on 31.12.06 : NIL
- The company will consider the effect of deferred tax asset/liability (AS- 22) in the audited accounts at the year end.
- Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

For Marksans Pharma Limited

Place: Mumbai

Date: 31st January, 2007

Mark Saldanha  
Managing Director